Key facts
- · Holder: Pvg Asset Management Corp · Percent: 8.3% · SCHEDULE 13G
- · Holder: The B Group, Inc. · Percent: 10% · SCHEDULE 13G
- · Holder: Laurence W. Lytton · Percent: 7.4% · SCHEDULE 13G
- · Holder: Eric Keller · Percent: 7.07% · SCHEDULE 13D
Retension Pharmaceuticals, Inc. has 4 Schedule 13D or 13G filings on record since 2026-10-14. 4 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| The B Group, Inc. | 10% | 833,333 | SCHEDULE 13G, 2026-10-16 | 2026-10-13 |
| Pvg Asset Management Corp | 8.3% | 1,002,050 | SCHEDULE 13G, 2026-10-16 | 2026-10-09 |
| Laurence W. Lytton | 7.4% | 617,207 | SCHEDULE 13G, 2026-10-15 | 2026-10-13 |
| Eric Keller | 7.07% | 598,598 | SCHEDULE 13D, 2026-10-14 | 2026-10-13 |
Holding shares or following this stake? See who's behind Retension Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Want the whole picture on Retension Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Retension Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Retension Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Eric Keller
The Reporting Person acquired beneficial ownership of the securities reported herein in as Chief Executive Officer, a member of the board of directors (the "Board") and a co-founder of the Issuer, for investment purposes, and as compensation from the Issuer. In his capacity as Chief Executive Officer and a member of the Board of the Issuer, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Person expects to review from time to time his investment in the Issuer and may, depending on the market and other conditions and applicable legal requirements, (i) purchase or acquire additional shares of Common Stock in the open market, in privately negotiated transactions, or otherwise; (ii) sell or dispose of all or a portion of the shares of Common Stock now beneficially owned or hereafter acquired by him; and (iii) engage in communications with, without limitation, other officers and employees of the Issuer, other shareholders of the Issuer, members of the Board, or other relevant parties regarding the Issuer, including but not limited to its business, operations, governance, and control. Other than as described herein, the Reporting Person does not have any plans or proposals relating to or that would result in any of the events or matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, …The first part of Item 4 of the SCHEDULE 13D filed 2026-10-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-10-14 | Eric Keller | 7.07% | SCHEDULE 13D |
| 2026-10-15 | Laurence W. Lytton | 7.4% | SCHEDULE 13G |
| 2026-10-16 | Pvg Asset Management Corp | 8.3% | SCHEDULE 13G |
| 2026-10-16 | The B Group, Inc. | 10% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Retension Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.